Citius Pharmaceuticals, Inc. (CTXR) Form 8-K — Oct 26, 2026
Citius Oncology (Nasdaq: CTOR), majority-owned subsidiary of Citius Pharmaceuticals (Nasdaq: CTXR), announced preliminary fiscal Q4 2026 LYMPHIR unit sales showing 792 units purchased by U.S. wholesalers, up 120% from 360 units in the prior quarter. Institutional adoption also accelerated: 54 institutions have now ordered LYMPHIR versus 44 as of mid-August, and 950 vials were ordered by prescribing centers, keeping the company on pace toward its goal of formulary placement at 100 priority institutions by calendar year-end.
Key figures
- Fyq3 wholesaler units
- 360
- Fyq4 wholesaler units
- 792
- Institutions ordering
- 54
- Fyq3 institutional vials
- 926
- Fyq4 institutional vials
- 950
- Estimated ctcl market usd
- $400 million+
- Prior institutions ordering
- 44
- Formulary target institutions
- 100
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.